DPP4 and type 2 diabetes mellitus: In these phase III studies the DPP-4 inhibitors were examined as monotherapy in drug-naïve patients and as add-on to on-going therapy with metformin, sulfonylurea therapy, thiazolidinedione therapy and therapy with exogenous insulin in type 2 diabetes (Table 2).